PRME vs. IMCR, AAPG, KNSA, DYN, GPCR, ARDX, INDV, NRIX, VIR, and SNDX
Should you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include Immunocore (IMCR), Ascentage Pharma Group International (AAPG), Kiniksa Pharmaceuticals (KNSA), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), Ardelyx (ARDX), Indivior (INDV), Nurix Therapeutics (NRIX), Vir Biotechnology (VIR), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry.
Prime Medicine vs.
Prime Medicine (NYSE:PRME) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.
Prime Medicine has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.
Immunocore received 44 more outperform votes than Prime Medicine when rated by MarketBeat users. Likewise, 73.33% of users gave Immunocore an outperform vote while only 61.11% of users gave Prime Medicine an outperform vote.
Immunocore has higher revenue and earnings than Prime Medicine. Immunocore is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.
Prime Medicine currently has a consensus price target of $13.13, suggesting a potential upside of 336.05%. Immunocore has a consensus price target of $65.64, suggesting a potential upside of 120.07%. Given Prime Medicine's stronger consensus rating and higher possible upside, equities analysts plainly believe Prime Medicine is more favorable than Immunocore.
Prime Medicine has a net margin of 0.00% compared to Immunocore's net margin of -15.87%. Immunocore's return on equity of -12.84% beat Prime Medicine's return on equity.
In the previous week, Immunocore had 2 more articles in the media than Prime Medicine. MarketBeat recorded 3 mentions for Immunocore and 1 mentions for Prime Medicine. Immunocore's average media sentiment score of 0.99 beat Prime Medicine's score of 0.00 indicating that Immunocore is being referred to more favorably in the news media.
70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 23.5% of Prime Medicine shares are owned by company insiders. Comparatively, 9.1% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Immunocore beats Prime Medicine on 10 of the 18 factors compared between the two stocks.
Get Prime Medicine News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prime Medicine Competitors List
Related Companies and Tools
This page (NYSE:PRME) was last updated on 2/21/2025 by MarketBeat.com Staff
Free PRME Stock Alerts